Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Course objectives
- The promise of engineered models
- Why examine engineered mice?
- Production and validation of engineered models
- Types of engineered animals
- Transgenic mice by microinjection
- Knockout mice (gene targeting)
- Utilization of gene targeting technology
- Validation milestones for engineered models
- Characterization of genetically engineered animals
- Sample protocol for screening engineered animals
- Standardizing genetic and environmental variables
- Selecting the most appropriate engineered model
- Approaches to functional genomics
- Considerations for using engineered animals
- Engineered models in pharmaceutical research
- Pharmaceutical careers for engineered animals
- Screening for genetic toxicology
- Carcinogenicity testing with engineered mice
- Induced tumor rate in engineered models
- Industrial practice for carcinogenicity testing
- The Trp53 heterozygous mouse model
- The Tg.Ac mouse model
- rasH2 mouse model for short-term carcinogenicity
- Carcinogenicity assay - study design
- Carcinogenicity assay - hypothetical results
- Improvement in carcinogenicity testing
- Other mutant mouse models
- Mutagenicity testing with transgenic mice
- Abbreviations
- The molecular basis of the Big Blue mouse model
- Mutagenicity testing protocol
- The Big Blue mouse mutagenicity assay
- The Muta mouse mutagenicity assay
- In-vivo mutagenicity assay - study design
- Decision tree for carcinogenicity testing
- Engineered animals: assessing adverse outcomes
- Beta-secretase as a therapeutic target
- Impact of chronic beta-secretase blockade
- Artemin therapy for treating peripheral neuropathy
- Neural changes in adrenal after Artemin exposure
- Impact of Artemin supplementation
- Summary
- Further references
Topics Covered
- Engineered animals in drug development
- Why we use them
- How we generate them
- How we characterize them
- How we select which model to use
- How we use them
Links
Series:
Categories:
Talk Citation
Bolon, B. (2009, July 30). Non-clinical development of pharmaceuticals using engineered animal models [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 16, 2024, from https://doi.org/10.69645/WEFV7181.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Brad Bolon has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Hide